185 related articles for article (PubMed ID: 19738222)
1. Observations from the OMERACT Drug Safety Summit, May 2008.
Simon LS; Strand CV; Boers M; Brooks PM; Henry D; Tugwell PS
J Rheumatol; 2009 Sep; 36(9):2110-3. PubMed ID: 19738222
[TBL] [Abstract][Full Text] [Related]
2. How to ascertain drug safety in the context of benefit. Controversies and concerns.
Simon LS; Strand CV; Boers M; Brooks PM; Tugwell PS; Bombardier C; Fries JF; Henry D; Goldkind L; Guyatt G; Laupacis A; Lynd L; Macdonald T; Mamdani M; Moore A; Saag KG; Silman AJ; Stevens R; Tyndall A
J Rheumatol; 2009 Sep; 36(9):2114-21. PubMed ID: 19738223
[TBL] [Abstract][Full Text] [Related]
3. Standardizing assessment of adverse effects in rheumatology clinical trials. Status of OMERACT Toxicity Working Group March 2000: towards a common understanding of comparative toxicity/safety profiles for antirheumatic therapies.
Woodworth TG; Furst DE; Strand V; Kempeni J; Fenner H; Lau CS; Miller F; Day R; Lipani J; Brooks P
J Rheumatol; 2001 May; 28(5):1163-9. PubMed ID: 11361207
[TBL] [Abstract][Full Text] [Related]
4. Patient based methods for assessing adverse events in clinical trials in rheumatology. Progress report for the OMERACT Drug Toxicity Working Party. Outcome Measures in Rheumatology.
Gazarian M; Tugwell P; Boers M; Bombardier C; Brooks P; Day R; Strand V; Wells G
J Rheumatol; 1999 Jan; 26(1):207-9. PubMed ID: 9918265
[TBL] [Abstract][Full Text] [Related]
5. Introduction to special section: drug safety in the rheumatic diseases.
Lovell D
Arthritis Care Res (Hoboken); 2010 Jun; 62(6):747-8. PubMed ID: 20499388
[No Abstract] [Full Text] [Related]
6. [Fetal safety profile of drugs used in the treatment of inflammatory rheumatic diseases].
Falcão S; Mourão AF; Pimentão JB; Branco JC
Acta Reumatol Port; 2007; 32(4):323-31. PubMed ID: 18159198
[TBL] [Abstract][Full Text] [Related]
7. Was risk properly assessed in Carter, et al's safety assessment of tumor necrosis factor antagonists during pregnancy?
Winger EE; Reed JL
J Rheumatol; 2009 Sep; 36(9):2122; author reply 2123. PubMed ID: 19738224
[No Abstract] [Full Text] [Related]
8. Patient based method of assessing adverse events in clinical trials in rheumatology: the revised Stanford Toxicity Index.
Welch V; Singh G; Strand V; Fries J; Boers M; Ramey D; Day RO; Brooks P; Tugwell P; Clinch J; Kristjansson B
J Rheumatol; 2001 May; 28(5):1188-91. PubMed ID: 11361211
[TBL] [Abstract][Full Text] [Related]
9. Improving Benefit-harm Assessment of Therapies from the Patient Perspective: OMERACT Premeeting Toward Consensus on Core Sets for Randomized Controlled Trials.
Andersen KM; Cheah JTL; March L; Bartlett SJ; Beaton D; Bingham CO; Brooks PM; Christensen R; Conaghan PG; D'Agostino MA; de Wit M; Dueck AC; Goodman SM; Grosskleg S; Hill CL; Howell M; Mackie SL; Richards B; Shea B; Singh JA; Strand V; Tugwell P; Wells GA; Simon LS
J Rheumatol; 2019 Aug; 46(8):1053-1058. PubMed ID: 30647191
[TBL] [Abstract][Full Text] [Related]
10. The possible clinical application of pharmacogenetics in rheumatology.
Ferraccioli G
J Rheumatol; 2003 Dec; 30(12):2517-20. PubMed ID: 14719186
[No Abstract] [Full Text] [Related]
11. Drug therapy in adolescents with rheumatic diseases.
Schaller JG
Rev Rhum Engl Ed; 1997 Oct; 64(10 Suppl):194S-195S. PubMed ID: 9385680
[No Abstract] [Full Text] [Related]
12. Developing an OMERACT Core Outcome Set for Assessing Safety Components in Rheumatology Trials: The OMERACT Safety Working Group.
Klokker L; Tugwell P; Furst DE; Devoe D; Williamson P; Terwee CB; Suarez-Almazor ME; Strand V; Woodworth T; Leong AL; Goel N; Boers M; Brooks PM; Simon LS; Christensen R
J Rheumatol; 2017 Dec; 44(12):1916-1919. PubMed ID: 27744393
[TBL] [Abstract][Full Text] [Related]
13. Safe and well tolerated.
Fleischmann R; Goodson N; Elewaut D
Rheumatology (Oxford); 2011 Nov; 50(11):1942-3. PubMed ID: 21994400
[No Abstract] [Full Text] [Related]
14. Rheumatology. 3. Modern drug therapies and current guidelines in rheumatology nursing.
Hill J; Reay N
Nurs Times; 2002 Mar 7-13; 98(10):41-4. PubMed ID: 11921625
[No Abstract] [Full Text] [Related]
15. Pharmacoepidemiology and rheumatic disorders.
Chan KA; Hernandez-Diaz S
Rheum Dis Clin North Am; 2004 Nov; 30(4):835-50, vii. PubMed ID: 15488696
[TBL] [Abstract][Full Text] [Related]
16. Assessing the efficacy and safety of rheumatic disease treatments: obstacles and proposed solutions.
Felson DT
Arthritis Rheum; 2003 Jul; 48(7):1781-7. PubMed ID: 12847670
[No Abstract] [Full Text] [Related]
17. Standardizing assessment and reporting of adverse effects in rheumatology clinical trials II: the Rheumatology Common Toxicity Criteria v.2.0.
Woodworth T; Furst DE; Alten R; Bingham CO; Yocum D; Sloan V; Tsuji W; Stevens R; Fries J; Witter J; Johnson K; Lassere M; Brooks P
J Rheumatol; 2007 Jun; 34(6):1401-14. PubMed ID: 17552067
[TBL] [Abstract][Full Text] [Related]
18. [Individual and interdisciplinary treatment of rheumatic diseases in pregnancy].
Bolz M
Dtsch Med Wochenschr; 2008 Nov; 133(46):2415. PubMed ID: 18988135
[No Abstract] [Full Text] [Related]
19. Primer: establishing a clinical trial unit - regulations and infrastructure.
Fleischmann R
Nat Clin Pract Rheumatol; 2007 Apr; 3(4):234-9. PubMed ID: 17396109
[TBL] [Abstract][Full Text] [Related]
20. Antirheumatic drug therapy during pregnancy.
Soscia PN; Zurier RB
Bull Rheum Dis; 1997 Apr; 46(2):2-4. PubMed ID: 9104043
[No Abstract] [Full Text] [Related]
[Next] [New Search]
